{"filings":[{"id":509157,"accession_number":"0001178913-26-002797","cik":1607962,"company_name":"Lifeward Ltd.","ticker":"LFWD","form_type":"8-K","filed_at":"2026-05-19T12:37:24+00:00","items":["8.01"],"status":"ready","headline":"Lifeward appoints Keith D. Rose as Chief Medical Officer effective May 1, 2026","event_type":"leadership","confidence":"high","bullets":["Keith D. Rose, M.D. appointed Chief Medical Officer effective May 1, 2026.","Dr. Rose joined Lifeward in March 2023; most recently VP, Medical Affairs, Medical Director – Neurosciences.","Prior experience includes Medical Director at Biocodex and Clinical Research Scientist at Novocure (NVCR).","Holds M.D. from George Washington University; residency at Baylor College of Medicine."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":452721,"accession_number":"0001178913-26-002727","cik":1607962,"company_name":"Lifeward Ltd.","ticker":"LFWD","form_type":"8-K","filed_at":"2026-05-15T12:00:26+00:00","items":["2.02"],"status":"ready","headline":"Lifeward Q1 revenue down 22%, net loss widens to $10.8M; cash improves to $11.4M","event_type":"earnings","confidence":"high","bullets":["Revenue $3.9M (down 22% YoY); AlterG sales fell 38% to $2.1M on supply chain timing.","Net loss $10.8M ($6.70/share) vs $4.8M ($5.53/share) in Q1 2025; one-time $4.9M R&D charge.","Unrestricted cash $11.4M at Mar 31, 2026, up from $2.2M at Dec 31, 2025; $6.5M from Oratech.","Operating cash burn improved 33% YoY to $3.7M; ReWalk exoskeleton sales up 11% to $1.6M.","Strategic transaction closed: $10M financing, Oratech acquisition with oral insulin Phase 2 trial."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94062,"accession_number":"0001178913-26-002212","cik":1607962,"company_name":"Lifeward Ltd.","ticker":"LFWD","form_type":"8-K","filed_at":"2026-04-23T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Lifeward VP of Strategy and Market Access Jeannine Lynch to depart May 3, 2026","event_type":"leadership","confidence":"high","bullets":["Jeannine Lynch's employment terminated as VP Strategy and Market Access, effective May 3, 2026.","Termination treated as without cause; severance per Employment Agreement dated July 9, 2021.","No replacement named in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106162,"accession_number":"0001178913-26-001944","cik":1607962,"company_name":"Lifeward Ltd.","ticker":"LFWD","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Lifeward regains Nasdaq audit committee compliance with three new appointees","event_type":"other_material","confidence":"high","bullets":["Nasdaq confirmed on March 30, 2026 that Lifeward now complies with Listing Rule 5605(c)(2)(A) after audit committee appointments.","Deficiency arose from resignation of director Hadar Levy; cure period allowed until February 2027 or sooner.","Appointed to audit committee: Moshe Rozenbaum, William Mark Sigsbee, Yehuda Reznick.","The matter is now closed with no further action required."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106161,"accession_number":"0001178913-26-001724","cik":1607962,"company_name":"Lifeward Ltd.","ticker":"LFWD","form_type":"8-K","filed_at":"2026-03-25T23:59:59+00:00","items":["2.01","1.01","3.02","5.02","9.01"],"status":"ready","headline":"Lifeward completes acquisition of Oratech Pharma, issues shares and convertible notes","event_type":"m_and_a","confidence":"high","bullets":["Lifeward completed acquisition of Oratech Pharma on March 25, 2026, issuing 2,256,476 ordinary shares and pre-funded warrants to Oramed.","Issued $10,000,000 aggregate principal amount of senior secured convertible notes and warrants in a private placement.","Directors Dr. John William Poduska and Randel Richner resigned effective March 25, 2026.","Appointed Nadav Kidron, Miriam Kidron, and Yehuda Reznick as new directors, expanding board from five to eight.","Entered into a First Amendment and Assignment to assign Oratech Pharma rights to Oratech Ltd."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106160,"accession_number":"0001178913-26-001574","cik":1607962,"company_name":"Lifeward Ltd.","ticker":"LFWD","form_type":"8-K","filed_at":"2026-03-20T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Lifeward receives Nasdaq notice for audit committee non-compliance after director resignation","event_type":"regulatory","confidence":"high","bullets":["Audit committee reduced to two members following Hadar Levy's board resignation.","Nasdaq requires audit committee of at least three members; cure period extends to Feb 24, 2027 or next annual meeting.","If annual meeting before Aug 24, 2026, compliance must be achieved by Aug 24, 2026.","No immediate effect on listing; shares continue trading on Nasdaq under LFWD."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106159,"accession_number":"0001178913-26-001106","cik":1607962,"company_name":"Lifeward Ltd.","ticker":"LFWD","form_type":"8-K","filed_at":"2026-03-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lifeward posts Q4 revenue $5.1M (-33% YoY); enters Oramed deal for oral insulin platform","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $5.1M (-33% YoY); full year $22.0M (-14% YoY). ReWalk exoskeleton sales +20% in Q4.","Net loss narrowed 65% to $5.3M ($3.60/share) in Q4; full year $19.9M ($17.16/share).","GAAP gross margin 38.2% in 2025 (non-GAAP 40.9%); operating expenses down 25%.","Cash $2.2M at Dec 31, 2025; expects up to $47M funding from Oramed upon closing strategic deal.","Shareholders approved Oramed deal: Lifeward acquires POD oral insulin tech; Oramed gets up to 49.99% equity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106158,"accession_number":"0001178913-26-000875","cik":1607962,"company_name":"Lifeward Ltd.","ticker":"LFWD","form_type":"8-K","filed_at":"2026-03-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Lifeward shareholders approve Oratech Pharma acquisition and related proposals","event_type":"other_material","confidence":"high","bullets":["Proposal 1 passed: issuance of ordinary shares to Oramed for Oratech acquisition (1,854,591 for, 470,084 against).","Proposal 2 passed: election of two external directors contingent on closing of Oratech acquisition.","Proposal 5 passed: equity grant to CEO Mark Grant (1,656,670 for, 674,846 against).","Proposal 6 passed: reappointment of Ernst & Young as auditor for FY 2026 (6,175,644 for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106157,"accession_number":"0001178913-26-000823","cik":1607962,"company_name":"Lifeward Ltd.","ticker":"LFWD","form_type":"8-K","filed_at":"2026-03-11T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Lifeward regains Nasdaq minimum bid price compliance; delisting risk resolved","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice confirming compliance with Minimum Bid Price Requirement (Rule 5550(a)(2)).","Company maintained closing bid price of at least $1.00 for 10 consecutive business days (Feb 24 – Mar 9, 2026).","Nasdaq has closed this matter; no further action required for this deficiency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106156,"accession_number":"0001178913-26-000673","cik":1607962,"company_name":"Lifeward Ltd.","ticker":"LFWD","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["3.03","5.03"],"status":"ready","headline":"Lifeward completes 1-for-12 reverse stock split to regain Nasdaq compliance","event_type":"other_material","confidence":"high","bullets":["18.34M shares consolidated to ~1.53M shares; authorized shares increased from 75M to 100M.","Reverse split effective Feb 24, 2026, approved by Finance Committee on Jan 30 and Feb 16.","Purpose: to meet Nasdaq minimum $1.00 bid price requirement for continued listing.","Fractional shares rounded down; warrants and options adjusted proportionately.","Trading symbol LFWD unchanged; new CUSIP M8216Q309."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106155,"accession_number":"0001178913-26-000654","cik":1607962,"company_name":"Lifeward Ltd.","ticker":"LFWD","form_type":"8-K","filed_at":"2026-02-27T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Lifeward director Hadar Levy steps down effective Feb 24, 2026","event_type":"leadership","confidence":"high","bullets":["Hadar Levy, Class I director, resigned from the Board on February 24, 2026.","Departure was not due to any disagreement with the Company's operations or policies.","No replacement has been named as of the filing date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106154,"accession_number":"0001178913-26-000642","cik":1607962,"company_name":"Lifeward Ltd.","ticker":"LFWD","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["3.02","8.01"],"status":"ready","headline":"Lifeward acquires IP and technology from Skelable for up to $500,000 in shares and cash","event_type":"m_and_a","confidence":"high","bullets":["Consideration includes up to $500,000, with $480,000 paid in Lifeward ordinary shares and $20,000 in cash, subject to milestone conditions.","Shares priced at the higher of the prior day's closing price or VWAP on the Nasdaq Capital Market.","Certain Skelable key employees will enter new employment agreements with Lifeward.","Initial closing expected in the near future; shares issued under Section 4(a)(2) exemption.","Agreement includes standard representations, warranties, and customary closing conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106153,"accession_number":"0001178913-26-000578","cik":1607962,"company_name":"Lifeward Ltd.","ticker":"LFWD","form_type":"8-K","filed_at":"2026-02-19T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"Lifeward enters $525K secured note with Oramed at 24% interest, expandable by $975K","event_type":"debt","confidence":"high","bullets":["Initial principal $525,000; mutual consent can increase by up to $975,000 for total up to $1.5M.","Interest at 24% per annum; matures earlier of August 12, 2026 or failure to obtain shareholder approval.","Note secured by lien on company's cash; proceeds applied ratably with existing $3M secured note.","Customary covenants limit additional debt, liens, asset sales, and affiliate transactions.","Events of default include non-payment, covenant breach, insolvency, or material adverse effect."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106152,"accession_number":"0001178913-26-000345","cik":1607962,"company_name":"Lifeward Ltd.","ticker":"LFWD","form_type":"8-K","filed_at":"2026-02-09T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Lifeward gets 180-day Nasdaq bid-price extension to Aug 3, 2026; 1-for-12 reverse split approved","event_type":"regulatory","confidence":"high","bullets":["Nasdaq gave Lifeward 180-day extension until Aug 3, 2026 to meet $1.00 bid price rule.","Company failed to regain compliance by Feb 2, 2026 initial deadline; deficiency letter Aug 5, 2025.","Shareholders approved reverse split up to 1-for-12 in Jan 2026; board controls timing.","Company may use reverse split to boost share price but no guarantee of compliance.","If not compliant by Aug 3, 2026, Nasdaq will start delisting process; appeal possible."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106151,"accession_number":"0001178913-26-000244","cik":1607962,"company_name":"Lifeward Ltd.","ticker":"LFWD","form_type":"8-K","filed_at":"2026-01-28T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Lifeward schedules March 12 meeting to vote on Oratech acquisition from Oramed; board to expand to 8","event_type":"m_and_a","confidence":"high","bullets":["EGM on March 12, 2026 to approve issuance of shares to Oramed as consideration for acquiring all of Oratech.","Upon closing, board to consist of 8 members: 3 from Lifeward, 3 from Oramed, and 2 external directors.","Oramed would hold at least 45% (potentially >49.99%) of voting power, triggering change-of-control rules.","Other proposals: election of external directors, increase in 2025 incentive plan shares, CEO equity grant, auditor reappointment.","Definitive proxy statement expected to be filed on or about February 9, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106150,"accession_number":"0001178913-26-000132","cik":1607962,"company_name":"Lifeward Ltd.","ticker":"LFWD","form_type":"8-K","filed_at":"2026-01-13T23:59:59+00:00","items":["1.01","2.03","3.02","5.02","7.01","9.01"],"status":"ready","headline":"Lifeward acquires Oramed's POD tech; Oramed gets up to 49.99% LFWD stake; up to $47M capital","event_type":"m_and_a","confidence":"high","bullets":["Issues Oramed shares & pre-funded warrants for 49.99% fully diluted equity (max 45% post-closing).","Up to $47M from Oramed & another investor via $20M convertible notes (8% interest, 100% warrant coverage) and equity.","Oramed to receive 4% of ReWalk net sales for up to 10 yrs; board expands to 6 (2 each from LFWD, Oramed, 2 external).","Oramed funds/manages POD clinical program; $10M note funded at close, second $10M conditional on revenue or share price milestone.","Transaction subject to shareholder approval; 120-day lock-up for officers, directors, and Oramed shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106149,"accession_number":"0001178913-26-000081","cik":1607962,"company_name":"Lifeward Ltd.","ticker":"LFWD","form_type":"8-K","filed_at":"2026-01-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Lifeward shareholders approve reverse split (1:2-1:12), capital increase, par value elimination","event_type":"other_material","confidence":"high","bullets":["Proposal 1 (reverse split authorization): 5,473,874 for, 2,084,129 against; Board to set ratio and effective date.","Proposal 2 (conditional authorized capital increase): 5,343,641 for, 2,149,990 against.","Proposal 3 (eliminate ordinary share par value): 5,037,563 for, 1,506,673 against.","Quorum of 41.7% (7,620,593 shares) present at January 6, 2026 Extraordinary General Meeting.","All three proposals passed; reverse split ratio range 1-for-2 to 1-for-12 at Board discretion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122444,"accession_number":"0001178913-25-004087","cik":1607962,"company_name":"Lifeward Ltd.","ticker":"LFWD","form_type":"8-K","filed_at":"2025-12-19T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Lifeward Chairperson Joseph Turk steps down; Robert J. Marshall Jr. appointed successor","event_type":"leadership","confidence":"high","bullets":["Joseph Turk resigns as Class I director and Board chairperson effective Dec 31, 2025; no disagreement with company.","Robert J. Marshall Jr. appointed as new chairperson effective Jan 1, 2026.","Turk's departure not related to any disagreement on operations, policies, or practices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122443,"accession_number":"0001178913-25-003837","cik":1607962,"company_name":"Lifeward Ltd.","ticker":"LFWD","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["1.01","2.02","2.03","3.02","9.01"],"status":"ready","headline":"Lifeward Q3 revenue $6.2M (+1% YoY); net loss $0.20/shr; secures $3M loan from Oramed","event_type":"earnings","confidence":"high","bullets":["Revenue $6.2M (+1% YoY); traditional products up 24% to $3.1M; AlterG down 15% to $3.1M.","GAAP net loss $3.2M ($0.20/shr); non-GAAP net loss $3.0M ($0.19/shr) vs $4.0M ($0.45/shr) YoY.","Cash used in ops $3.8M (down from $4.5M YoY); unrestricted cash $2.0M at quarter end.","Entered $3.0M secured loan from Oramed at 15%, convertible at $0.45/shr, matures May 2026.","Reaffirmed FY2025 guidance: revenue $24-26M; non-GAAP net loss $12-14M."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":16953000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122442,"accession_number":"0001178913-25-003509","cik":1607962,"company_name":"Lifeward Ltd.","ticker":"LFWD","form_type":"8-K","filed_at":"2025-10-16T23:59:59+00:00","items":["2.02"],"status":"ready","headline":"Lifeward reports preliminary Q3 revenue $6.2M, cash $2.0M","event_type":"earnings","confidence":"medium","bullets":["Preliminary Q3 2025 revenue approximately $6.2 million, unaudited.","GAAP operating expenses estimated between $5.8M and $5.9M.","Cash and cash equivalents as of Sep 30, 2025 were about $2.0 million.","Amounts are preliminary, subject to completion of quarter-end close and financial review.","Independent auditor EY has not audited or reviewed these preliminary results."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":16953000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139138,"accession_number":"0001178913-25-002900","cik":1607962,"company_name":"Lifeward Ltd.","ticker":"LFWD","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lifeward Q2 revenue $5.7M (-15% YoY); net loss $6.6M; resets 2025 guidance","event_type":"earnings","confidence":"high","bullets":["Revenue $5.7M, down 15% YoY; traditional product revenue $2.5M (-19% YoY) excluding one-time Medicare benefit.","Net loss $6.6M ($0.58 per share) vs $4.3M ($0.50) in Q2 2024; includes $2.8M goodwill impairment.","Adjusted net loss $3.5M ($0.31 per share); cash burn improved to $3.9M from $5.6M prior year.","Record number of ReWalk units placed for Medicare since fee schedule; new CEO Mark Grant and CFO Almog Adar appointed.","FY 2025 guidance reset to revenue $24-26M and non-GAAP net loss $12-14M."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":10758000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139137,"accession_number":"0001178913-25-002836","cik":1607962,"company_name":"Lifeward Ltd.","ticker":"LFWD","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Lifeward appoints Almog Adar as CFO, effective August 1, 2025","event_type":"leadership","confidence":"high","bullets":["Almog Adar, previously VP of Finance and CAO, named CFO effective August 1, 2025.","Adar receives annual base salary of $315,000 and bonus potential up to 35% of base.","Granted option to purchase 225,000 ordinary shares, vesting over four years.","Retention period through Dec 31, 2025 includes $80,000 retention payment plus up to 7% of base in individual metrics.","Severance provisions include 6 months salary continuation; 12 months if termination occurs near a Change of Control."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139136,"accession_number":"0001178913-25-002704","cik":1607962,"company_name":"Lifeward Ltd.","ticker":"LFWD","form_type":"8-K","filed_at":"2025-08-08T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Lifeward receives Nasdaq bid price deficiency notice; shares face potential delisting","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on Aug 5, 2025; closing bid below $1.00 for 30 consecutive business days.","Has 180 days until Feb 2, 2026 to regain compliance by closing bid price ≥$1.00 for 10 consecutive days.","May be eligible for an additional 180-day extension if meeting other listing standards.","If not cured, Nasdaq will initiate delisting; company may appeal to a hearings panel.","Company to monitor and consider options but no assurance of regaining compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139135,"accession_number":"0001178913-25-002629","cik":1607962,"company_name":"Lifeward Ltd.","ticker":"LFWD","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Lifeward shareholders reject ratification of equity grant for director Randel Richner; 2025 Incentive Plan approved","event_type":"other_material","confidence":"high","bullets":["Proposal 5 failed: 811,866 for vs 993,112 against (excluding 3.4M broker non-votes).","Proposals 1-4 and 6-8 passed: reelected directors, ratified CEO pay, approved 2025 Incentive Plan, increased authorized shares, reappointed auditor.","Quorum of 5,223,471 shares (45.0% of outstanding) present at August 1, 2025 annual meeting.","2025 Incentive Compensation Plan authorizes stock-based awards to officers, directors, and employees.","Board Chairperson granted double the annual fee/equity of other directors effective meeting date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156672,"accession_number":"0001178913-25-002251","cik":1607962,"company_name":"Lifeward Ltd.","ticker":"LFWD","form_type":"8-K","filed_at":"2025-06-26T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Lifeward closes $2.6M public offering of 4M shares and warrants","event_type":"other_material","confidence":"high","bullets":["Offering of 4M units at $0.65/unit, each consisting of 1 ordinary share + 1 warrant.","Ordinary warrants exercisable at $0.65/share, expire 5 years from issuance.","Net proceeds expected ~$2.0M for commercial efforts, working capital, general purposes.","Placement agent H.C. Wainwright received 7% cash fee, expense allowance, and 240K warrants at $0.8125.","30-day lock-up on share issuance; one-year ban on variable rate transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156671,"accession_number":"0001178913-25-002190","cik":1607962,"company_name":"Lifeward Ltd.","ticker":"LFWD","form_type":"8-K","filed_at":"2025-06-16T23:59:59+00:00","items":["5.02","5.08"],"status":"ready","headline":"Lifeward appoints Mark Grant as director, Jasinski resigns from board","event_type":"leadership","confidence":"high","bullets":["Board increased from 7 to 8; Mark Grant appointed Class II director effective June 15, 2025.","Grant previously appointed President and Co-CEO effective June 2, 2025; no extra compensation for board role.","Larry Jasinski resigns from board effective June 30, 2025; remains Co-CEO until then, then advisory role through end of 2025.","Annual Meeting set for August 1, 2025; shareholder proposals due by June 23, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156670,"accession_number":"0001178913-25-002034","cik":1607962,"company_name":"Lifeward Ltd.","ticker":"LFWD","form_type":"8-K","filed_at":"2025-06-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Lifeward CFO Michael Lawless resigns effective June 27, 2025","event_type":"leadership","confidence":"high","bullets":["Michael Lawless notified resignation as CFO and Principal Financial Officer on June 2, 2025.","Resignation effective June 27, 2025, or earlier date as agreed with the Company.","Departure is for personal reasons, not due to any disagreement with Company or auditors.","No replacement named in the filing; succession plan not disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156669,"accession_number":"0001178913-25-001862","cik":1607962,"company_name":"Lifeward Ltd.","ticker":"LFWD","form_type":"8-K","filed_at":"2025-05-19T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Lifeward appoints Mark Grant as President and CEO, effective June 2, 2025","event_type":"leadership","confidence":"high","bullets":["Mark Grant will become CEO on June 2; Larry Jasinski serves as Co-CEO through June 30, then advisory through 2025.","Grant received inducement option grant of 400,000 shares, vesting over 4 years, at closing price on grant date.","Employment agreement includes $435,000 base salary, up to 70% annual bonus, and severance provisions.","Grant brings 30 years of healthcare leadership, most recently as President of Americas at Medtronic and IMRA Surgical.","Transition is planned; Jasinski will remain available on an as-needed basis through end of 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}